Medtronic (NYSE:MDT) is a leading global healthcare technology company that develops and manufactures medical devices and therapies. It operates in various segments, including cardiac and vascular, minimally invasive therapies, restorative therapies, and diabetes. Medtronic competes with other major players in the medical device industry, such as Johnson & Johnson and Boston Scientific.
On November 18, 2025, Medtronic reported earnings per share (EPS) of $1.36, surpassing the Zacks Consensus Estimate of $1.31. This marks an improvement from the previous year's EPS of $1.26, highlighting the company's growth. The positive earnings report reflects strong demand across various end markets and a healthy volume of medical procedures.
Medtronic's revenue for the quarter reached approximately $8.96 billion, exceeding the estimated $8.87 billion. This revenue growth has led the company to increase its fiscal-year outlook, indicating confidence in sustaining its growth trajectory. The company's optimistic forecast is supported by its strong financial performance and market demand.
Following the earnings report, Medtronic's stock experienced an uptick, capturing the attention of investors. The company's price-to-earnings (P/E) ratio is approximately 25.9, indicating the price investors are willing to pay for each dollar of earnings. The price-to-sales ratio stands at about 3.55, reflecting the market's valuation of its revenue.
Medtronic's enterprise value to sales ratio is around 3.50, suggesting how the market values the company's total worth relative to its sales. The enterprise value to operating cash flow ratio is approximately 17.0, indicating the company's valuation in relation to its cash flow from operations. With an earnings yield of about 3.86% and a current ratio of 1.02, Medtronic maintains a balanced liquidity position.
